Literature DB >> 10438857

An inducible human immunodeficiency virus type 1 (HIV-1) vector which effectively suppresses HIV-1 replication.

D S An1, K Morizono, Q X Li, S H Mao, S Lu, I S Chen.   

Abstract

Recently, gene therapy vectors based upon the human immunodeficiency virus type 1 (HIV-1) genome have been developed. Here, we create an HIV-1 vector which is defective for all HIV-1 genes, but which maintains cis-acting elements required for efficient packaging, infection, and expression. In T cells transduced by this vector, vector expression is low but efficiently induced following HIV-1 infection. Remarkably, although the HIV-1 vector does not contain specific anti-HIV-1 therapeutic genes, the presence of the vector alone is sufficient to inhibit the spread of HIV-1 infection. The mechanism of inhibition is likely to be at the level of competition for limiting substrates required for either efficient packaging or reverse transcription, thereby selecting against propagation of wild-type HIV-1. These results provide proof of a concept for potential application of a novel HIV-1 vector in HIV-1 disease.

Entities:  

Mesh:

Year:  1999        PMID: 10438857      PMCID: PMC104294     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  40 in total

1.  Gene therapy: hopes, hypes, and hurdles.

Authors:  I M Verma
Journal:  Mol Med       Date:  1994-11       Impact factor: 6.354

2.  A conditionally replicating HIV-1 vector interferes with wild-type HIV-1 replication and spread.

Authors:  B Dropulić; M Hĕrmánková; P M Pitha
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

3.  Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors.

Authors:  T Kafri; U Blömer; D A Peterson; F H Gage; I M Verma
Journal:  Nat Genet       Date:  1997-11       Impact factor: 38.330

4.  Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector.

Authors:  H Miyoshi; M Takahashi; F H Gage; I M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-16       Impact factor: 11.205

5.  Molecular determinants of acute single-cell lysis by human immunodeficiency virus type 1.

Authors:  J Cao; I W Park; A Cooper; J Sodroski
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

Review 6.  Human gene therapy--an immature genie, but certainly out of the bottle.

Authors:  T Friedmann
Journal:  Nat Med       Date:  1996-02       Impact factor: 53.440

7.  High-efficiency gene transfer into CD34+ cells with a human immunodeficiency virus type 1-based retroviral vector pseudotyped with vesicular stomatitis virus envelope glycoprotein G.

Authors:  R K Akkina; R M Walton; M L Chen; Q X Li; V Planelles; I S Chen
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

8.  In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector.

Authors:  L Naldini; U Blömer; P Gallay; D Ory; R Mulligan; F H Gage; I M Verma; D Trono
Journal:  Science       Date:  1996-04-12       Impact factor: 47.728

9.  Fate of the human immunodeficiency virus type 1 provirus in infected cells: a role for vpr.

Authors:  V Planelles; F Bachelerie; J B Jowett; A Haislip; Y Xie; P Banooni; T Masuda; I S Chen
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

Review 10.  Transfer of genes to humans: early lessons and obstacles to success.

Authors:  R G Crystal
Journal:  Science       Date:  1995-10-20       Impact factor: 47.728

View more
  36 in total

1.  Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by HIV-1-based lentivirus vectors expressing transdominant Rev.

Authors:  M R Mautino; N Keiser; R A Morgan
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

2.  Antibody-directed targeting of retroviral vectors via cell surface antigens.

Authors:  K Morizono; G Bristol; Y M Xie ; S K Kung; I S Chen
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

3.  Fine-tuning of T-cell receptor avidity to increase HIV epitope variant recognition by cytotoxic T lymphocytes.

Authors:  Michael S Bennett; Aviva Joseph; Hwee L Ng; Harris Goldstein; Otto O Yang
Journal:  AIDS       Date:  2010-11-13       Impact factor: 4.177

4.  Human immunodeficiency virus type 1 vpr induces apoptosis through caspase activation.

Authors:  S A Stewart; B Poon; J Y Song; I S Chen
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

5.  Mobilization-competent Lentiviral Vector-mediated Sustained Transcriptional Modulation of HIV-1 Expression.

Authors:  Anne-Marie W Turner; Justin De La Cruz; Kevin V Morris
Journal:  Mol Ther       Date:  2008-12-09       Impact factor: 11.454

6.  Reply to "Coadaptive stability of interfering particles with HIV-1 when there is an evolutionary conflict".

Authors:  Igor M Rouzine; Leor S Weinberger
Journal:  J Virol       Date:  2013-09       Impact factor: 5.103

7.  Lentivirus-delivered stable gene silencing by RNAi in primary cells.

Authors:  Sheila A Stewart; Derek M Dykxhoorn; Deborah Palliser; Hana Mizuno; Evan Y Yu; Dong Sung An; David M Sabatini; Irvin S Y Chen; William C Hahn; Phillip A Sharp; Robert A Weinberg; Carl D Novina
Journal:  RNA       Date:  2003-04       Impact factor: 4.942

8.  Human immunodeficiency virus type 1 Vpr-mediated G2 arrest requires Rad17 and Hus1 and induces nuclear BRCA1 and gamma-H2AX focus formation.

Authors:  Erik S Zimmerman; Junjie Chen; Joshua L Andersen; Orly Ardon; Jason L Dehart; Jana Blackett; Shailesh K Choudhary; David Camerini; Paul Nghiem; Vicente Planelles
Journal:  Mol Cell Biol       Date:  2004-11       Impact factor: 4.272

9.  Primary cell model for activation-inducible human immunodeficiency virus.

Authors:  Bryan Burke; Helen J Brown; Matthew D Marsden; Gregory Bristol; Dimitrios N Vatakis; Jerome A Zack
Journal:  J Virol       Date:  2007-05-02       Impact factor: 5.103

10.  Design requirements for interfering particles to maintain coadaptive stability with HIV-1.

Authors:  Igor M Rouzine; Leor S Weinberger
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.